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Traumatic brain injury (TBI) represents a critical health problem of which diagnosis, 
management, and treatment remain challenging. TBI is a contributing factor in approxi-
mately one-third of all injury-related deaths in the United States. The Centers for Disease 
Control and Prevention estimate that 1.7 million people suffer a TBI in the United States 
annually. Efforts continue to focus on elucidating the complex molecular mechanisms 
underlying TBI pathophysiology and defining sensitive and specific biomarkers that can 
aid in improving patient management and care. Recently, the area of neuroproteomics– 
systems biology is proving to be a prominent tool in biomarker discovery for central 
nervous system injury and other neurological diseases. In this work, we employed the 
controlled cortical impact (CCI) model of experimental TBI in rat model to assess the 
temporal–global proteome changes after acute (1 day) and for the first time, subacute 
(7 days), post-injury time frame using the established cation–anion exchange chromatog-
raphy-1D SDS gel electrophoresis LC–MS/MS platform for protein separation combined 
with discrete systems biology analyses to identify temporal biomarker changes related 
Abbreviations: AD, Alzheimer’s disease; AnxA5, annexin A5; CaM, calmodulin; CaMBP, calmodulin-binding proteins; CAX-
PAGE, cation–anion exchange chromatography-1D SDS gel electrophoresis; CCI, controlled cortical impact; CNS, central 
nervous system; CRYM, thyroid hormone-binding protein μ-crystallin; LDH-B, l-lactate dehydrogenase B chain; MMIF, 
macrophage migration inhibitory factor; NF, neurofascin; PACSIN, protein kinase C and casein kinase substrate in neurons 
protein 1; Pin1, peptidyl-prolyl cis-trans isomerase A; RPLC–MS/MS, reversed-phase liquid chromatography tandem mass 
spectrometry; SOD, superoxide dismutase; TBI, traumatic brain injury.
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to this rat TBI model. Rather than focusing on any one individual molecular entity, we 
used in silico systems biology approach to understand the global dynamics that govern 
proteins that are differentially altered post-injury. In addition, gene ontology analysis of 
the proteomic data was conducted in order to categorize the proteins by molecular 
function, biological process, and cellular localization. Results show alterations in several 
proteins related to inflammatory responses and oxidative stress in both acute (1 day) 
and subacute (7 days) periods post-TBI. Moreover, results suggest a differential upreg-
ulation of neuroprotective proteins at 7 days post-CCI involved in cellular functions such 
as neurite growth, regeneration, and axonal guidance. Our study is among the first to 
assess temporal neuroproteome changes in the CCI model. Data presented here unveil 
potential neural biomarkers and therapeutic targets that could be used for diagnosis, 
for treatment and, most importantly, for temporal prognostic assessment following 
brain injury. Of interest, this work relies on in silico bioinformatics approach to draw its 
conclusion; further work is conducted for functional studies to validate and confirm the 
omics data obtained.
Keywords: proteomics, traumatic brain injury, controlled cortical impact, biomarker, prognosis and therapeutics, 
inflammation, oxidative stress
inTrODUcTiOn
Traumatic brain injury (TBI) is a major health concern for which 
diagnosis, care management, and treatment remain challenging. 
Each year, approximately 1.7 million people sustain a TBI in the 
United States, out of which 52,000 die, 275,000 are hospitalized, 
and 1.365 million are treated and released from emergency care. 
Importantly, TBI is a contributing factor to a third (30.5%) of all 
injury-related deaths in the United States (1–3). TBI also accounts 
for a larger percentage of injuries and casualties among United 
States military personnel serving in Iraq and Afghanistan compared 
to previous conflicts, mainly due to the prevalent use of improvised 
explosive device and the high incidence of mild blast-overpressure 
exposure resulting in TBIs of various severities (4). The growing 
number of TBI cases among military personnel and civilians has 
brought new urgency to research efforts aimed at developing 
improved TBI diagnostic, prognostic, and treatment assays.
Neurological examination by the Glasgow Coma Scale (GCS) 
has been traditionally employed to assess acute TBI. However, 
this clinical tool has a number of limitations making it often 
inaccurate to categorizing TBI severity in patients (5). In most 
cases, clinical TBI status may be difficult to determine due to 
confounding medical treatments such as sedatives, opioids, or 
neuromuscular blocking agents (6, 7) and to illicit drug use and/
or alcohol intake (8–10). The evolving nature of brain injury 
progression can further complicate GCS assessment. Current 
imaging methods such magnetic resonance imaging (MRI) and 
computer tomography (CT) provide more objective information 
on the magnitude and localization of the injury. However, CT 
scans lack the sensitivity to detect mild to moderate diffuse brain 
injury, and the availability and feasibility of MRI acutely limit 
their broad clinical application (11, 12). Taken together, these 
limitations and challenges illustrate the need for facile, rapid, and 
reliable alternate methods to assess brain injury.
Efforts to elucidate the complex mechanisms of TBI progres-
sion and seek sensitive and specific biomarkers that can aid in 
optimizing TBI prognosis at acute and chronic long-term time 
points have been the main focus in the field of brain neurotrauma. 
Biomarker research has produced several putative, candidate 
TBI markers that can be derived from brain tissue, blood, and 
cerebrospinal fluid (CSF). These biomarkers are often assessed 
via various immunoassays, such as Western blotting or enzyme-
linked immunosorbent assay (ELISA). For instance, our group 
has examined the accumulation of spectrin and its calpain-
cleaved breakdown products in the CSF and brain tissue follow-
ing TBI (13–15). In addition, our recent studies using controlled 
cortical impact (CCI) model have demonstrated progressive 
brain pathologies in white matter involving myelin loss, delayed 
microvascular damage, and appearance of focal microbleeds 
that are temporally and regionally associated with punctate 
blood–brain barrier breakdown and upregulation of the glial and 
inflammatory biomarkers in the brain tissue starting from 24 h 
and progressing over 3 months following experimental TBI (16). 
S-100β, a calcium binding protein, has been used as well as severe 
TBI marker in serum (17–19) and CSF (20–22). Additionally, 
the concentration of myelin basic protein is elevated in human 
serum collected from pediatric TBI patients (18). Further, Tau 
proteins have been associated with elevated intracranial pressure, 
a symptom or component of TBI (23), and phosphorylated tau 
has been identified in serum up to several months after severe TBI 
(24). Nevertheless, despite the identification of these biomarkers 
via targeted approaches, many of them suffer from lack of TBI 
specificity and may not indicate TBI chronic temporal changes.
Recently, bioinformatics and in particular the applica-
tion of neuroproteomic strategies to central nervous system 
(CNS) injuries has emerged as a promising biotechnology for 
identifying novel pathways and biological processes relevant to 
TBI pathophysiology, as well as pointing out which key genes/
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proteins may serve as potential biomarkers and therapeutic drug 
targets (25–29). The potential of neuroproteomics platforms have 
been explored using acute paradigms of TBI (26, 27, 29–35), 
spinal cord injury (36–44), and cerebral ischemia or stroke (34, 
45–50). Our group has previously reported TBI effects upon the 
global proteome where we combined cyanine labeling with SDS 
PAGE–capillary LC–MS/MS to study hippocampal tissue (30). 
Results from this work provided a framework for subsequent 
rapid and comprehensive sequence-specific biomarker discovery 
strategies that are currently used in our laboratory. This strategy 
employs tandem strong cation–anion exchange chromatography 
(first dimension) followed by 1D gel electrophoresis (second 
dimension) prior to LC–MS/MS of tryptic peptides extracted 
from the gel. This “bottom up” protein identification revealed 
59 differentially expressed proteins (of which 21 were decreased 
and 38 were increased) in cortical tissue collected 48 h after CCI 
in rats (26). Nonetheless, studying TBI at multiple time points 
by MS/MS-based proteomics remains crucial, as it enables the 
correlation of relative protein expression to disease progression 
in experimental TBI animal models, which can be translated to 
clinical outcome metrics.
In this present work, we employed the well-established rat 
CCI model to examine the global proteomic differences between 
acute (1  day post-CCI) and subacute (7  days post-CCI) TBI 
using the cation–anion exchange chromatography-1D SDS gel 
electrophoresis (CAX-PAGE) LC–MS/MS platform (26, 45). 
We then combined the temporal neuroproteomic response with 
systems biology strategies to infer time-dependent changes in 
cellular pathways caused by CCI. We also applied systems biology 
analyses to identify non-redundant pathways relevant to TBI at 
these different time points and conducted gene ontology analyses 
of the proteomics data to categorize the differentially expressed 
proteins by molecular function, biological process, and cellular 
localization. To the best of our knowledge, this study is among 
the first to assess the TBI protein dynamic changes associated 
with temporal resolution. Data from this work can be translated 
clinically to discover new potential biomarkers and therapeutic 
targets for TBI that could be used to better treat or prevent seque-
lae associated with this disease.
MaTerials anD MeThODs
animal housing conditions
Animal handling and processing were conducted in compliance 
with the National Institutes of Health Guidelines for Animal 
Research (Guide for the Care and Use of Laboratory Animals) and 
according to the laws of the USA and regulations of the Department 
of Agriculture. They were also approved by Institutional Animal 
Care and Use Committee (IUCAC) at the University of Florida. 
Rats were maintained and housed under pathogen-free condi-
tions with constant temperature and humidity control.
implementation of In Vivo controlled 
cortical impact in rats
A digital electromagnetic CCI device (Benchmark™ Stereotaxic 
Impactor, MyNeurolab, USA) was used to model TBI in male 
Sprague-Dawley rats as described previously (16). A total of three 
groups were prepared with each group having seven rats. A total of 
21 rats were divided into 3 groups, a craniotomy group, 1 day TBI, 
and 7 days TBI. For the TBI procedure, each rat was mounted in a 
stereotactic frame, and the right cortex (ipsilateral) was impacted 
with a 4-mm diameter impactor tip at a velocity of 3.5 m/s to a 
depth of 2.5 mm, at 1 day (n = 5) and 7 days (n = 5) post-CCI. 
Prior to surgery, rats were anesthetized (45  mg ketamine/kg, 
5 mg xylazine/kg) by intraperitoneal injection. An adequate level 
of anesthesia was determined by monitoring the corneal reflex 
and withdrawal to painful stimuli for hind limbs. The injured rats 
were sacrificed by decapitation. From each group, we used five 
rats for our proteomics analysis, which has been validated to be 
statistically significant (26, 35, 51–53). For our control animals, 
sham-injured rats were subjected to identical surgical procedures 
but did not receive an impact injury.
Brain Tissue collection and  
Protein extraction
Ipsilateral cortical brain tissue samples were rapidly dissected, 
washed with cold saline, sip frozen in liquid nitrogen then stored 
at −80°C until use. Brain tissues were pulverized into a powder 
over dry ice then solubilized in lysis buffer containing 1% (v/v) 
Triton X-100, 1 mM dithiothreitol (DTT), and one tablet protease 
inhibitor cocktail per 10 mL of total solution (Roche Diagnostics, 
IN, USA). The brain lysates were then centrifuged at 15,000 × g 
for 5 min at 4°C to remove insoluble debris. Protein concentra-
tions were determined by detergent compatible (DC) protein 
assay (Bio-Rad, CA, USA).
cation–anion exchange chromatography-
1D sDs gel electrophoresis
A well-characterized offline multidimensional protein separation 
platform compatible with applying high throughput proteomic 
technology for biomarker identification was applied to this study 
according to the already published protocol (26, 27). In brief, this 
platform consisted of ion chromatography, which was composed 
of a sulfopropyl-strong cation exchange column (SCX-S1) and 
a quaternary ammonium-strong anion (SAX-Q1) modified 
sepharose prepacked ion-exchange columns (Bio-Rad). Purified 
cortical tissue protein lysates from each of the three groups (the 
craniotomy group, 1 day post-CCI, 7 days post-CCI) were pooled 
to achieve a requisite protein quantity of 1 mg per single CAX 
injection and to average inconsistent protein levels due to bio-
logical variability. Similar buffers and separation protocols were 
used as published (52, 53). UV chromatograms were collected 
at a wavelength of 280  nm for each run. Each 1-mL fractions 
was concentrated using Millipore YM-10 centrifugal filters 
(Millipore, MA, USA). Also, 20 μL of 2× Laemmli sample buffer 
(Invitrogen, NY, USA) was added to the YM-10 collection filters 
prior to collection by centrifugation at 1,000 × g for 3 min. For 
technical reproducibility, this experiment was repeated three 
times to compare each of the five control samples to their cor-
responding CCI samples (five samples for 1  day post-CCI and 
five samples for 7  days post-CCI). Protein concentration was 
measured afterward as a conformational step. Protein fractions 
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were then run side-by-side (i.e., craniotomy fraction 1, CCI day 1 
fraction 1, CCI day 7 fraction 1) on an 18-well, 10–20% gradient 
Tris–HCl Bio-Rad Criterion (Bio-Rad, CA, USA) gels for dif-
ferential comparison of sham controls and the five CCI samples 
at each 1 and 7  days post-CCI. Gel bands were visualized and 
assessed for their intensity as described below.
gel Band Visualization and  
Densitometric analysis
Gel bands were visualized by Coomassie blue staining (Bio-Rad, 
Hercules CA, USA). Quantitative densitometric analysis of 
select gel band intensities was performed using Image J software 
(Version 1.6, National Institutes of Health. Bethesda, MD, USA). 
Differential bands were manually identified and selected as 
regions of interest based on molecular weight estimation. The 
relative intensity in protein band fold change was derived by 
comparing intensity ratios among the sham control group, CCI 
day 1, and CCI day 7 and was calculated by dividing the greater 
value by the lesser value and adding a negative sign to indicate 
decrease after CCI. Any bands with fold change greater than 1.5 
were selected for subsequent differential protein identification.
reversed-Phase liquid chromatography 
Tandem Mass spectrometry
Nano-reversed-phase liquid chromatography tandem mass 
spectrometry (RPLC–MS/MS) was employed for protein separa-
tion and identification using the same parameters as recently 
published by our group (53). Nanoflow was performed on a 
NanoAcquity UPLC (Waters, Milford, MA, USA); the autosam-
pler was used to load 2 μL of each sample onto a 5-μm particle 
size Symmetry 180 μm × 20 mm C18 trapping column at 4 μL/
min for 10 min. Then, the sample plug was loaded onto a 1.7 μM 
particle size BEH130 C18 100 μm × 100 mm analytical column at 
300 nL/min. The mobile-phase consisted of solvent A (water with 
0.1% formic acid) and solvent B (acetonitrile with 0.1% formic 
acid). Separation was achieved within a run time of 115 min at 
a flow rate of 300 nL/min. The first linear gradient was from 1 
to 40% B over 90 min; the second linear gradient was from 40 
to 100% B over 5  min and held for 5  min before returning to 
initial mobile-phase composition (1%B). Tandem mass spectra 
were collected on LTQ-XL (Thermo, San Jose, CA, USA) using a 
data dependent acquisition method in Xcalibur 2.0.7 (Thermo), 
in which data-dependent scanning was specified as a criterion to 
select the top 10 most abundant ions using 11 separate scan events 
at a given chromatographic time point (115 min) for subsequent 
analysis. The mass spectrometer was set to perform a full-scan 
and subsequently MS/MS scans on the 10 most intense ions in 
the full-scan spectrum MS (scan event 1) with dynamic exclusion 
were enabled. Dynamic exclusion temporarily puts a mass into an 
exclusion list after its MS/MS spectrum is acquired, providing the 
opportunity to collect MS/MS information on the second most 
intense ion from the full-scan spectrum MS (scan event 1). All 
MS/MS spectra were analyzed using Proteome Discoverer 1.3 
(Thermo), SEQUEST (version: 1.3.0.339), and X! Tandem [ver-
sion: CYCLONE (2010.12.01.1)]. Database search engines were set 
up to search a trypsin-indexed uniprot-Rattus + norvegicus.fasta 
(accessed on 2015, 35,126 entries). The search was achieved using 
the average mass for matching the precursor with a fragment ion 
mass tolerance of 0.8 Da and a parent ion tolerance of 2.00 Da and 
a maximum of two missed cleavage sites. Carbamidomethylation 
(+57 Da) of cysteine was selected as a static modification, while 
the oxidation of methionine was selected as a dynamic modifica-
tion. Using the output from SEQUEST and X! Tandem, Scaffold 
(version: Scaffold_3.3.3, Proteome Software) was used to validate, 
organize, and interpret mass spectrometry data. Peptide identifi-
cations were accepted if they could be established at greater than 
95.0% probability as specified by the Peptide Prophet algorithm. 
Protein identifications were accepted if they could be established 
at greater than 99.9% probability and contained at least two 
peptides.
neurosystems Biology and gene Ontology 
analysis and statistical Testing
Neurosystems biology analyses were conducted using the 
Elsevier’s Pathway Studio v. 10.0 (Elsevier, MD, USA) to construct 
non-redundant pathways relevant to the two different injury time 
points. This software was used to interpret biological meaning 
from gene (protein) expression, build and analyze pathways, 
and find relationships among genes, proteins, cell processes, and 
diseases as indexed by the ResNet database (54, 55). “Subnetwork 
Enrichment Analysis” (SNEA) algorithm was selected to extract 
statistically significant altered biological and functional pathways 
pertaining to each identified set of protein hits in our study. 
The algorithm compares the subnetwork distribution to the 
background distribution using one-sided Mann–Whitney U-test 
and calculates a p-value indicating the statistical significance of 
difference between two distributions.
Separate lists of International Protein Index (IPI) accession 
numbers of the identified upregulated and downregulated pro-
teins for 1 and 7 days post-CCI were imported into the Pathway 
Studio. In each group, the upregulated proteins were assigned 
a value of +3, and the downregulated proteins were assigned a 
value of −3. The network analysis included a search for direct 
interactions and shortest paths between the identified proteins 
to map biologically relevant networks and identify relevant 
cellular processes. For a more comprehensive understanding 
of the classes of proteins found in the CCI model, we used the 
PANTHER bioinformatics analysis (http://www.pantherdb.org/
genes/batchIdSearch.jsp) utilizing rat protein ontology database 
to classify proteins into distinct categories of molecular function 
and biological process. Integrated Venn diagram analysis was 
performed using the “InteractiVenn”: a web-based tool for the 
analysis of complex data sets (56).
resUlTs
combined caX-Page
This study employed a previously established neuroproteomics 
approach applied to TBI studies by our group (13–15) (Figure 1). 
Our experimental design required pooled ipsilateral cortical 
lysates (n = 5) from control craniotomy and injured rats (1 and 
7  days post-CCI). The proteins in each sample were resolved 
FigUre 2 | caX chromatographic separation of sham control and cci 
(1 and 7 days). Overlaid CAX chromatograms of pooled rat cortical lysates 
(n = 5) are shown at 214 nm absorbance and the gradient profile. Thirty 
1-mL fractions were collected from each pooled sample lysate for SDS-PAGE 
separation.
FigUre 1 | schematic diagram of the differential caX-Page-lc–Ms/Ms proteomics platform used for the TBi study. Proteins in the pooled extracts 
were resolved in two dimensions, first by cation–anion exchange chromatography followed by 1D-SDS-PAGE. Differential bands were selected, excised for in gel 
trypsin digestion, and analyzed by data dependent LC–MS/MS. Protein database search against a rat database generated a list of proteins with altered expression. 
The identified differential proteins were subjected to neurosystems biology pathway analysis.
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using two-dimensional CAX-PAGE. Samples from either (1) 
craniotomy control group, (2) 1 day post-CCI, or (3) 7 days post-
CCI were sequentially separated by tandem strong cation and 
anion exchange chromatography according to protein charge. 
The overlaid CAX chromatograms of the sham control and 
the two injured groups illustrate differences among the three 
experimental groups particularly in intensity in some regions 
(Figure 2).
Thirty, consecutive 1-mL fractions collected from each CAX 
separation were grouped (i.e., fraction 1 of sham control, frac-
tion 1 of 1 day post-CCI, and fraction 1 of 7 days post-CCI) and 
loaded side-by-side onto a 1D gel to further resolve the proteins 
in the second dimension. A total of 42 differential bands were 
selected and excised from the gel for subsequent proteomic 
analysis as boxed and labeled in Figure 3. Relative fold changes 
were calculated between control and CCI (1 and 7 days) as shown 
in Figure 4, and bands with fold change greater than 1.5 were 
selected for subsequent differential protein identification. In 
the 1 day post-CCI group, half of the gel bands had decreased 
intensity and the other half of bands had increased intensity 
(Figure 4A). However, in 7 days post-CCI, 14 bands showed a 
decrease in intensity, and 28 gel bands showed an increase in 
intensity (Figure 4B).
identification of Differential Proteins by 
lc–Ms/Ms at 1 and 7 days Post-cci
Following the gel densitometric analysis, 42 bands showing altered 
expression in either 1 or 7 days post-CCI were selected for LC–
MS/MS analysis (Figure 3). Tables S1 and S2 in Supplementary 
Material summarize the identified proteins for each band with 
their corresponding peptide spectral data, sequence coverage and 
the directionality of the band intensities. In the 1 day post-CCI 
group, a total of 63 proteins were altered, of which 21 were only 
upregulated, 38 were only downregulated, and 4 were found to be 
identified in gel bands that expressed up/downregulation trends 
(Table S3 in Supplementary Material). While in 7 days post-CCI, 
a total of 56 proteins showed altered expression, with 41 proteins 
displaying increase in abundance alone, 13 proteins displaying 
decrease in abundance only, and 2 were found to demonstrate an 
increase and decrease in abundance at the same time (Table S4 in 
Supplementary Material).
Unique and common Upregulated and 
Downregulated Proteins at 1 and 7 days 
Post-cci
In order to scrutinize the differences in protein expression at 1 
and 7 days post-CCI, unique and common upregulated and/or 
downregulated proteins were identified between the two studied 
FigUre 3 | side-by-side sDs-Page separation of caX fractions. The 1-mL fractions collected from CAX separation were concentrated and loaded onto 
1D-SDS-PAGE. Differential gel bands were selected (boxed and labeled) for trypsin digestion. In 1 day post-CCI, a total of 83 altered proteins were identified (47 
upregulated vs. 36 downregulated) in the bands with fold change of 1.5 or more. In 7 days post-CCI, a total of 64 proteins were identified to be altered (47 
upregulated and 17 downregulated) in the bands with fold change of 1.5 or more. N = Sham control, T1 = CCI day 1, T7 = CCI day 7. The numbers above each 
lane (topmost) are the CAX fraction number.
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groups. There are 19 common proteins that showed an increase 
in abundance at both 1 and 7 days post-CCI (Table 1), including 
complement C3, peptidyl-prolyl cis-trans isomerase A (Pin1), 
elongation factor 2, protein kinase C and casein kinase substrate 
in neurons protein 1 (PACSIN), etc. Conversely, 15 common 
proteins were found to be downregulated at both time points 1 
and 7 days post-CCI (Table 1), including superoxide dismutase 
(SOD), neurofascin (NF), calmodulin (CaM), etc.
Interestingly, some proteins were identified to be uniquely 
upregulated or downregulated at either 1 or 7  days post-CCI 
(Table  2). Indeed, 10 proteins were identified to be uniquely 
upregulated or downregulated at 1  day post-CCI (Table  2), 
while only 3 proteins were found to be exclusively upregulated at 
7 days post-CCI (Table 2). Of those proteins showing an altered 
expression unique to day 1 or 7 are vinculin and protein-disulfide 
isomerase, which are differentially expressed at day 1, and annexin 
A5 (AnxA5), l-lactate dehydrogenase B chain (LDH-B), and 
thyroid hormone-binding protein μ-crystallin (CRYM) homolog, 
which are upregulated at day 7 only.
Temporal network analysis of altered 
Proteins at 1 and 7 days Post-cci
To further understand the difference in protein expression at 
the cellular level post-CCI between 1 and 7  days, analysis of 
the specific enriched pathways was performed. The analysis of 
neuroproteomics data generated interaction maps as presented 
in Figure 5. The network was generated using the “direct interac-
tion” algorithm to map cellular process and interactions between 
altered proteins. The red color represents upregulated proteins in 
day 1 injury onset, while the blue color shows proteins that are 
downregulated. In the 1 day post-CCI group, the majority of the 
proteins are associated with apoptosis, inflammatory response, 
oxidative stress, and autophagy (Figure  5A). The proteins 
FigUre 4 | Densitometric gel band analysis. Differential band intensities of selected control and CCI bands were quantified using ImageJ densitometry software. 
(a) 1 day post-CCI and (B) 7 days post-CCI fold changes relative to the control. Forty gel bands were found to have more than 1.5-fold increase, and 30 gel bands 
were found to have more than 1.5-fold decrease in density.
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identified in the 7-day post-CCI samples were also found to 
be involved not only in apoptosis, inflammatory response, and 
oxidative stress but also in ischemia as well as cell regeneration 
and cell growth (Figure 5B).
gene Ontology analysis of the 
Differentially expressed Proteins  
at 1 and 7 days Post-cci
For a more comprehensive understanding of the classes of proteins 
found in the different brain injury samples (1 vs. 7 days), we used 
the PANTHER application for the rat protein ontology database 
to classify proteins into distinct categories. Data were defined by 
biological processes and molecular functions (Figure 6). For 1 day 
post-CCI, 59 assignments obtained for biological processes were 
sorted into 13 classifications (Figure 6A), while 142 molecular 
functions were sorted into 8 classifications (Figure 6B). Similarly, 
for 7  days post-CCI, 52 assignments obtained for biological 
processes were categorized into 13 classifications (Figure  6C), 
whereas 119 molecular function were sorted into 8 classifications 
(Figure 6D). The classification categories exceeded the number 
of proteins, and this is due to the fact that some proteins may be 
assigned more than one molecular function and biological pro-
cess. Percentages listed represent the number of proteins linked 
with a particular functional block normalized to the total number 
of proteins at each time point. Interestingly, the same biological 
processes and molecular functions were enriched at 1 and 7 days 
post-CCI but with differences noted in percentages of proteins 
corresponding to each functional block.
DiscUssiOn
Traumatic brain injury imposes a substantial public burden 
where diagnosis, management, and treatment remain challeng-
ing. With an estimated 10 million people affected annually by 
TBI worldwide, it is predicted by the World Health Organization 
(WHO) that by the year 2020, TBI will surpass many diseases to 
become the third leading cause of global mortality and disability 
(57). Efforts have been made and continue to focus on elucidating 
the complex molecular mechanisms underlying TBI pathophysi-
ology and defining specific biomarkers for this disease. Recently, 
bioinformatics and in particular neuroproteomic studies have 
proven to be a contemporary and convenient tool in biomarker 
discovery for many human diseases including CNS injury. In this 
study, we employed our rat CCI model to decipher mechanistic 
changes underlying TBI at the level of the proteome after 1 day 
(acute) and, for the first time, 7 days (subacute) following TBI 
injury.
The high throughput nature of proteomic studies generates 
tremendous amount of data. Systems biology has been considered 
latest contemporary domain in biological science that aims for 
a system-level elucidation of complex biological processes (58). 
Rather than focusing on the individual molecular entity, systems 
biology seeks to understand the system dynamics that govern 
protein networks and the functional set of proteins that regulate 
decisions related to the disease or injury.
In our study, the multidimensional CAX-PAGE RPLC–MS/
MS proteomic platform was utilized to identify proteome 
changes in acute (1  day post-CCI) and subacute (7  days 
TaBle 1 | common upregulated and downregulated differentially altered proteins between the two different time points.
Band identified proteins accession no. calc. M.W.  
(kDa)
gel M.W.  
(kDa)
gel band densitometry 
condirection
Day 1 Day 7
(a) Upregulated proteins
4A Peptidyl-prolyl cis-trans isomerase A (Pin1)* IPI00387771 18 17 ↑ ↑
7B Ba1-667 IPI00196656 107 75 ↑ ↑
9B Elongation factor 2* IPI00203214 95 87 ↑ ↑
10C Elongation factor 2* IPI00203214 95 85 ↑ ↑
9B Cytoplasmic aconitate hydratase IPI00207003 98 87 ↑ ↑
10A Complement C3* IPI00480639 186 200 ↑ ↑
12A Complement C3 (fragment) IPI00480639 186 200 ↑ ↑
10C GMP synthase [glutamine-hydrolyzing] IPI00372214 77 85 ↑ ↑
12B Heat shock cognate 71 kDa protein IPI00208205 71 80 ↑ ↑
12C Dihydropyrimidinase-related protein 2 IPI00870112 62 55 ↑ ↑
12C Isoform 2 of dihydropyrimidinase-related protein 3 IPI00203250 74 55 ↑ ↑
12C Dihydropyrimidinase-related protein 5 IPI00331981 62 55 ↑ ↑
12C Isoform M1 of pyruvate kinase isozymes M1/M2 IPI00231929 58 55 ↑ ↑
12C WD repeat-containing protein 1 IPI00215349 66 55 ↑ ↑
14A Alpha-1-inhibitor 3* IPI00201262 164 220 ↑ ↑
16A Alpha-1-inhibitor 3* IPI00201262 164 145 ↑ ↑
16A Isoform 1 of murinoglobulin-1 IPI00212666 165 145 ↑ ↑
16B Serum albumin IPI00191737 69 55 ↑ ↑
16C Creatine kinase B-type IPI00470288 43 40 ↑ ↑
16C Protein kinase C and casein kinase substrate in neurons protein 1 (PACSIN)* IPI00208245 50 40 ↑ ↑
16C Gamma-enolase* IPI00326412 47 40 ↑ ↑
22A Brain acid soluble protein 1 IPI00231651 22 80 ↑ ↑
(B) Downregulated proteins
5A Aconitate hydratase, mitochondrial* IPI00421539 85 85 ↓ ↓
7A Aconitate hydratase, mitochondrial* IPI00421539 85 85 ↓ ↓
5B Superoxide dismutase [Mn], mitochondrial (MnSOD)* IPI00211593 25 16 ↓ ↓
6B Superoxide dismutase [Mn], mitochondrial (MnSOD)* IPI00211593 25 23 ↓ ↓
6A Triosephosphate isomerase* IPI00231767 27 27 ↓ ↓
6B Triosephosphate isomerase* IPI00231767 27 23 ↓ ↓
6A Gluthathione S-transferase (fragment) IPI00231150 26 27 ↓ ↓
6A Gluthathione S-transferase Mu1 IPI00231639 26 27 ↓ ↓
6B Protein DJ-1* IPI00212523 20 23 ↓ ↓
6C Macrophage migration inhibitory factor (MMIF)* IPI00230907 12 12 ↓ ↓
14B 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-1 IPI00192534 138 140 ↓ ↓
14B Ubiquitin-like modifier-activating enzyme 1 IPI00368347 118 140 ↓ ↓
14B Isoform 1 of neurofascin (NF)* IPI00206666 138 140 ↓ ↓
14C Dihydropyrimidinase-related protein 2 IPI00870112 62 60 ↓ ↓
20C Calreticulin IPI00191728 48 52 ↓ ↓
20D Calmodulin (CaM)* IPI00231955 17 16 ↓ ↓
21A Heat shock cognate 71 kDa protein IPI00208205 71 70 ↓ ↓
21A Isoform 1 of syntaxin-binding protein 1 IPI00205372 68 70 ↓ ↓
(A) Nineteen proteins were identified to be commonly upregulated at 1 and 7 days post-CCI.
(B) Fifteen proteins were identified to be commonly downregulated at 1 and 7 days post-CCI.
*Proteins of high interest relevant to our study.
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post-CCI) TBI. This study provides an assessment of the global 
temporal changes in protein expression in contrast to our earlier 
single time point TBI proteomic study at 48  h post-trauma 
(26). Similar to the latter study, the altered TBI proteome is 
contrasted against the sham cortical proteome. A total of 63 
proteins were altered in acute TBI, where 21 were upregulated, 
38 were downregulated, and 4 were upregulated and down-
regulated simultaneously. On the other hand, 56 proteins were 
identified to have changed in abundance in subacute TBI, with 
41 proteins showing increase in expression, 13 proteins show-
ing decrease in expression, and 2 proteins revealing increased 
and decreased expression together. The total number of altered 
proteins in this study is higher compared to our previous study, 
where a total of 66 proteins were identified at 1 and 7 days post-
CCI, while 59 proteins were identified at 48 h post-TBI in the 
cortical tissue. Proteins with altered expression following TBI 
TaBle 2 | Unique upregulated and downregulated differentially altered proteins at each time point.
Band identified proteins accession  
no.
calc. M.W.  
(kDa)
gel M.W.  
(kDa)
gel band densitometry 
condirection
Day 1 Day 7
(a) Unique altered proteins at 1-day post-cci
3A Peptidyl-prolyl cis-trans isomerase FKBP1A IPI00231434 12 13 ↑ −
3A Zero beta-1 globin* IPI00207146 16 13 ↑ −
8A Vinculin* IPI00365286 117 75 ↑ −
10B Complement inhibitory factor H* IPI00208659 140 150 ↑ −
15B Alpha-enolase* IPI00464815 47 45 ↑ −
8C Alpha-enolase* IPI00464815 47 50 ↓ -
20B Protein-disulfide isomerase (PDI)* IPI00198887 57 55 ↑ −
8C Isoform mitochondrial of fumarate hydratase, mitochondrial IPI00231611 54 50 ↓ -
8D Stathmin IPI00231697 17 18 ↓ -
8D Cofilin-1 IPI00327144 19 18 ↓ -
8D Protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 
(predicted), isoform CRA_a
IPI00870306 18 18 ↓ -
(B) Unique altered proteins at 7 days post-cci
12D Annexin A5 (AnxA5)* IPI00471889 36 29 − ↑
12D l-lactate dehydrogenase B chain (LDH-B)* IPI00231783 37 29 − ↑
12D μ-crystallin homolog (CRYM)* IPI00214448 34 29 − ↑
(A) Ten proteins were identified to be uniquely upregulated or downregulated at 1 day post-CCI.
(B) Three proteins were identified to be uniquely upregulated at 7 days post-CCI.
*Proteins of high interest relevant to our study.
FigUre 5 | Molecular and biological pathway interaction map analysis of altered proteins from the cci samples (1 vs. 7 days post-cci). Using 
Pathway Studio 9.0, altered proteins relevant to CCI at different time points were analyzed. The network was generated using “direct interaction” algorithm to map 
biological processes and interactions among altered proteins. Several processes believed to be central to the pathogenesis of CCI were identified using this search. 
(a) Examples of those processes including apoptosis, inflammatory response, oxidative stress, and autophagy were shown to be altered at day 1. (B) Similarly, at 
day 7, processes including apoptosis, inflammatory response, oxidative stress, ischemia as well as cell regeneration and cell growth were shown to be altered. The 
red color represents upregulated proteins, while the blue color signifies proteins that are downregulated.
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were either upregulated or downregulated in response to injury. 
Here, systems biology approach was utilized to identify altered 
cellular processes and pathways associated with the differential 
proteome of acute and subacute TBI.
There are 15 proteins showing decreased abundance in both 
acute and subacute TBI (Table 1B). Among these are proteins 
such as macrophage migration inhibitory factor (MMIF), aconi-
tate hydratase (aconitase), SOD, NF, and CaM. MMIF is a brain 
FigUre 6 | Molecular functions (MFs) and biological processes (BPs) depicting proteins that are altered in response to cci at 1 and 7 days are 
shown in pie charts. Proteins are classified into families and subfamilies of shared function, which are then categorized using a highly controlled vocabulary 
(ontology terms) by biological process (a,c) and molecular function (B,D). At 1 day post-CCI, 59 assignments were obtained for biological process and were sorted 
into 13 categories (a), while 142 molecular functions obtained were arranged into 8 classifications (B). At 7 days post-CCI, 52 assignments were obtained for 
biological process and sorted into 13 classifications (c), whereas 119 molecular functions obtained were sorted into 8 categories (D). Some proteins may be 
assigned for more than one molecular function and biological process. The percentages listed are calculated as the number of proteins associated with a particular 
functional block normalized to the total number of proteins.
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inflammatory mediator that has been shown to be elevated 1 day 
post-TBI (59). Although it is also increased in Alzheimer’s disease 
(AD) and mild cognitive impairment (60), our results showed 
that MMIF expression is decreased at 1 and 7 days post-CCI. This 
may contribute to the presence of other downstream proteins 
regulating MMIF function in the brain. Aconitate hydratase 
(aconitase) was also shown to be downregulated at acute and 
subacute time points in this present work. Studies reveal that 
loss of cellular aconitase activity can been used as an index of 
oxidative stress damage (61, 62).
Superoxide dismutase is another oxidative stress-related pro-
tein. It is present in very small amounts in the extracellular matrix 
to remove excess superoxide anions that are released following 
TBI. Experiments performed on rats with cerebral contusion 
have shown that administration of exogenous lecithinized SOD 
reduces edema produced by superoxide ions post-TBI (63, 64). 
In our study, SOD was downregulated (nearly twofold change) at 
1 day post-CCI, with a greater decrease in expression of around 
fivefold change at 7 days post-CCI. This is consistent with a previ-
ous study done on mice with brain injury, where SOD levels were 
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significantly lower in the TBI group compared with the sham 
group (65). Interestingly, SOD may serve as a therapeutic target 
in TBI, where studies assessing the potential protective effect 
of SOD2 following brain injury have shown that ameliorating 
its expression in mice exhibited enhanced neuroprotection and 
decreased oxidative stress (65, 66). Also, the overexpression of 
manganese superoxide dismutase (MnSOD) protected tissues 
from radiation by reducing experimental inflammation (67), 
which can be further tried in TBI.
Additionally, CaM, a Ca2+ sensor, which showed decrease 
in expression in acute and subacute TBI, is known to mediate 
critical signaling functions through binding and regulating 
a diverse population of downstream targets referred to as 
calmodulin-binding proteins (CaMBPs). In TBI, our group 
developed a novel proteomic method that identified a total of 
69 potential CaMBPs, of which 26 were known CaMBPs and 
43 were putative novel CaMBPs (68). A study evaluating the 
biochemical mechanisms contributing to memory loss post-TBI 
have showed that unselective activation of calcium/calmodulin-
dependent protein kinase II (CaMKII) signaling may disrupt 
the machinery for memory formation, resulting in this memory 
loss (69). Another study on calcineurin, a calcium/calmodulin-
dependent phosphatase, has also found that its isoforms are dif-
ferentially modulated by acute TBI in rats in a regionally specific 
manner (70). Future studies can be hence employed to further 
assess exactly the functions of CaM downstream targets in TBI, 
which may help improve current therapeutic interventions and/
or develop new treatments.
On the other hand, a total of 19 proteins showed increase in 
abundance in both acute and subacute TBI samples (Table 1A). 
Those include complement C3, Pin1, elongation factor 2, and 
PACSIN. The complement component C3 was found to be upreg-
ulated at both 1 and 7 days post-CCI, with higher expression at 
7 days. This protein is necessary for normal neutrophil extravasa-
tion comprising the inflammatory reaction in the brain following 
TBI (71). Also, it has been suggested that complement activation 
does not induce membrane-damaging effects in penetrating TBI 
(72) but rather C3-positive microglia and co-localization of both 
C3 and membrane-attack complex were found on cell bodies and 
axons of neurons at the TBI areas in rats (73). Thus, C3 may serve 
as a potential therapeutic target modulating the CNS inflamma-
tory injury (71).
In addition, Pin1 enzyme was highly expressed at both time 
points in our study. This protein has a neuroprotective role in 
the CNS where its ablation leads to premature aging and neuro-
degeneration. Patients with AD were found to have inactivated 
Pin1 in their neurons (74–76). Besides, studies have revealed that 
polymorphisms of the PIN-1 gene may affect neurodegenera-
tion in the hippocampal area, which may lead to mild cognitive 
impairment and eventually AD (77, 78). Hence, relevance of Pin1 
pathology to TBI may be taken into consideration in the future 
to assess its potential role in TBI-induced dementia and AD 
especially that many posttranslational modifications, which may 
follow protein synthesis, are similar between AD and TBI (79).
Another protein with increased abundance is PACSIN. 
Although its function in TBI is still unclear, a study has revealed 
the involvement of PACSIN in signal transduction to the 
cytoskeleton of neurons through phosphorylation by protein 
kinase C and casein kinase 2 (80–82). Importantly, this phos-
phorylation of casein kinase 2 has been proven to precipitate 
Rac1-dependent spine formation in dendrites of hippocampal 
neurons (83). Moreover, PACSINs play crucial roles in protein 
packing and tabulation activity through tip-to-tip and wedge 
loop-mediated lateral interactions on the surface of neuronal 
membranes (84), and they promote biogenesis of membrane-
trafficking intermediates by engaging with inositol 5-phosphatase 
(OCRL1) (85). Besides, a proteomic analysis of the hippocampus 
in early-stage AD model mice has revealed significant changes 
in the levels of 14 proteins, one of which is PACSIN 1 that was 
significantly increased (86). This consistency in the levels of 
certain proteins, such as PACSIN, between TBI and AD, points 
to a common mechanistic ground linking the pathophysiology of 
both maladies (79). More than that, many of the neuroprotective 
proteins that are overexpressed in TBI, with higher expression 
in subacute TBI, can serve as novel candidate biomarkers and 
potential targets for TBI in the future.
Some of the altered proteins identified in our proteomic 
analysis were unique to each time point as well, where 10 proteins 
were recognized at 1 day post-CCI alone, while 3 were unique to 
7 days post-CCI time point. Of the proteins that are altered at 
1 day post-CCI only are vinculin and protein-disulfide isomerase 
(Table 2A). Vinculin, an integrin complexing protein known to 
be associated with synaptic destabilization and process retraction, 
has been shown to dissociate from cellular membranes following 
TBI (87). It usually participates in anchoring actin filaments to 
the cell membrane and plays a crucial role in cell motility. In a 
study done to investigate the levels of actin-anchoring proteins 
vinculin, talin, and paxillin in rat brains following stab wound 
injury, it has been shown that astrocytes in the white matter 
stained positive for these proteins, while none of them was 
found in the cortex (88). In our study, vinculin was upregulated 
at 1  day post-CCI but not expressed after 7  days. Moreover, 
protein-disulfide isomerase, a stress protein that is overexpressed 
in response to hypoxia in primary-cultured glial cells, can have 
beneficial effects against brain ischemia and plays a critical role in 
resistance to ischemic damage through its effect against apoptotic 
cell death (89). It is also upregulated in acute TBI alone in our 
study. Also, three proteins were uniquely upregulated at 7 days 
post-CCI including AnxA5, LDH-B, and CRYM (Table  2B), 
which may have potential roles following injury and can serve 
as novel biomarkers for subacute TBI. AnxA5 induces neuronal 
membrane repair via the formation of a protective 2D bandage at 
the membrane damaged site (90). On the other hand, the increase 
in the levels of l-lactate dehydrogenase A chain (LDH-A) and 
decrease in LDH-B have been shown to contribute to high brain 
lactate levels, which are predictive of aging phenotypes (91). 
Finally, CRYM and thyroid hormone levels may be key factors in 
the development of the pipecolate pathway in the brain (92), espe-
cially that neonatal decrease in these hormones is well-known to 
influence brain development and cause mental retardation and 
neurological damage (93, 94).
Interestingly, our proteomics data analysis also revealed altera-
tion in a subset of proteins that have not been previously studied 
or tackled in TBI. For instance, at both 1 and 7 days post-CCI, 
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a number of proteins were found to be upregulated including 
elongation factor 2, alpha-1-inhibitor 3, and gamma-enolase 
(Table  1A). Eukaryotic elongation factor 2 is known to play a 
key role in regulating the protein translational machinery and 
controlling ribosomal movements across the mRNA, thus affect-
ing the survival of neurons in cases of elevated oxidative stress 
(95). Alpha-1-inhibitor 3, a protein of the alpha-macroglobulin 
family and an acute phase reactant protein, has been previously 
studied and shows a role in the early stages of the inflammatory 
response (96), yet it has never been studied in TBI. In addition, 
gamma-enolase, also known as neuron-specific enolase, possesses 
neuroprotective effects on cultured neurons from embryonic rat 
brain (97). On the other hand, a subset of proteins was found 
to be downregulated at both time points including triosephos-
phate isomerase, protein DJ-1, and isoform 1 of NF (Table 1B). 
Inhibition of triosephosphate isomerase was shown to induce 
neuronal death in cultured murine cortical cells, while protein 
DJ-1 possesses a neuroprotective role in Parkinson’s disease 
(98). The importance of those proteins is that they may serve 
as potential biomarkers and therapeutic targets for TBI, where 
future studies may be conducted to assess their exact function 
in the context of TBI. Moreover, other proteins that were found 
to be uniquely altered at each time point, such as alpha-enolase, 
complement inhibitory factor H, and zero beta-1 globin, and have 
never been studied in TBI, can also be assessed for their function 
in TBI (Table 2).
In order to scrutinize the differences in protein expression 
at a functional level, further analysis was carried forward using 
PANTHER software to identify enriched pathways and biological 
processes altered in TBI at different time points between acute 
and subacute states. This software is a unique resource that 
classifies genes and proteins by their functions using published 
scientific experimental evidence and evolutionary relationships 
abstracted by curators with the goal of predicting function 
even in the absence of direct experimental evidence. Proteins 
are classified into families and subfamilies of shared function, 
which are then categorized using a highly controlled vocabulary 
(ontology terms). In our study, common pathways were altered 
including apoptosis, inflammatory response, oxidative stress, and 
autophagy both at 1 and 7 days post-CCI. Yet, it is worthwhile to 
state that several cellular processes encompassing neuroprotective 
proteins were found to be enriched in subacute TBI, including cell 
regeneration, neurite outgrowth, axonogenesis, and cell growth. 
Interestingly, some pathways were found to be altered uniquely 
at 1 day post-CCI, such as cell migration, caspase, mitochondrial 
damage, neuron toxicity, and heat shock response, while others 
were found to be solely altered at 7  days post-CCI, including 
regeneration, axon guidance, axonogenesis, cell growth, and cell 
differentiation (Figure 5).
sTUDY liMiTaTiOns
This work builds on previous and current recent studies from 
our and other labs that have showed the capabilities of neuro-
proteomics in identifying putative markers of TBI (UCH-L1, 
synaptotagmin, and spectrins) utilizing the same CAX separation 
platform as the one applied here (26, 27, 52). Several of these 
markers have been patented and been translated to clinical set-
tings such as UCH-L1 and GFAP (19). However, this work has 
a number of limitations that relates to the study experimental 
design, methodology, and finally complying with the recent 
recommendation of the NIH common data elements (CDEs) for 
preclinical TBI (99).
First, our work was based on an in  silico bioinformatics 
approach lacking validation or confirmation steps via wet lab 
techniques; these experiments were kept for the follow-up 
functional analysis study where we selected few of the identified 
proteins to study their dynamic alteration. Second, our work 
has considered only two time points (1 vs. 7  days), while in 
reality, longer time points post-injury should be assessed to give 
a comprehensive overview of protein changes. Third, this work 
assessed only cortical regions, while the emphasis now is to look 
at different brain regions that can depict the global injury profile 
rather than being biased to the cortical areas. Therefore, future 
studies including multiple regions such as the hippocampus 
and thalamus will provide a better insight of the injury profile. 
Besides, this work is using the CCI model, which may not be truly 
the ideal TBI model to recapitulate the different TBI patholo-
gies. This will be gained in future studies through comparing 
our results to different models such as repetitive mild TBI, and 
consequently, analyzing clinical samples may be considered. It 
is likely that there will be common proteins/pathways retrieved; 
yet there also may be unique findings between focal, diffuse, 
or even axonal injury pathologies. As per the recommendation 
of the NIH CDEs for preclinical TBI, the use of female cohort 
should be included to highlight the diversity in injury profile and 
avoid any experimental bias; however, one should bear in mind 
that these neuroproteomics studies have their complexities and 
limitations in determining the number of samples to be used, the 
pooling consideration, and finally the time and cost they require. 
Finally, it is of interest to mention and highlight the shortcom-
ings of this proteomics and other high throughput approaches 
(MRI, transcriptomics, gene arrays, etc.) generating “big data,” 
which may be biased toward the instrumentation in use or the 
method of selection. This will often lead to the missing of big 
chunk of extremely valuable data from any experimental study. 
To illustrate this point, it is estimated that the human genome 
contains around 20,000 protein-encoding genes, while the total 
number of proteins in human cells is estimated to range between 
250,000 and one million. Nevertheless, any genomics study and/
or complementary proteomics platform will identify on average 
100–400 changed genes/proteins, which raises the question of the 
fate of other altered genes/proteins that have missed due to the 
methodology limitation. To conclude, this work utilizing systems 
biology concept has showed that it can highlight on several dif-
ferential pathways and proteins, which can be of high prognostic 
and diagnostic value. Several of the identified protein hits can be 
translated clinically as putative markers in clinical TBI.
cOnclUsiOn
As noted from the experimental model and results obtained, the 
aim of this work is to provide an overview of the altered protein 
dynamics that are commonly and/or uniquely altered in the acute 
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and subacute phases of experimental model of TBI. Collectively, 
data obtained from this work suggest that many of the differen-
tially identified proteins in the acute and subacute phases of TBI 
may serve as potential neural biomarkers and therapeutic targets 
for TBI. Of interest, the identification of the acute phase protein 
C3 seems to be a promising candidate marker that is easily meas-
ured in human TBI biofluids. Recently, there has been increased 
interest in the inflammatory markers in neurotrauma that can be 
coupled with neural specific protein to constitute a panel of TBI 
markers; several of these inflammatory markers have shown to 
be elevated clinically after severe TBI (100). Similarly, identified 
structural proteins constitute an interesting set of markers to be 
assessed post-injury time points, since these protein families 
have been among grass root of acute TBI biomarkers (βII–αII 
spectrins, ankyrins) (101–104).
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